Search Result

Results for "

Valproic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (8) Autophagy (14) Biochemical Assay Reagents (2) Caspase (1) Dihydroorotate Dehydrogenase (1) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (4) EBV (2) Endogenous Metabolite (16) Epoxide Hydrolase (2) HDAC (18) HIV (14) HSP (1) Isotope-Labeled Compounds (7) Mitophagy (14) Notch (14) Organoid (6) Reactive Oxygen Species (ROS) (1) Reference Standards (5)
By Research Areas:	Cancer (19) Infection (9) Inflammation/Immunology (1) Metabolic Disease (10) Neurological Disease (13)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10585

Valproic acid 60+ Cited Publications VPA; 2-Propylpentanoic acid; Dipropylacetic acid	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585A

Valproic acid sodium 60+ Cited Publications Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-B2117

Valpromide	Epoxide Hydrolase EBV	Infection Neurological Disease
Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle .

HY-10585R

Valproic acid (Standard) 45+ Cited Publications VPA (Standard); 2-Propylpentanoic acid (Standard); Dipropylacetic acid (Standard)	Reference Standards Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Dipropylacetic Acid) (Standard) is an analytical standard for valproic acid. This product is intended for research and analytical applications. Valproic acid is an orally active HDAC inhibitor (IC₅₀=0.5-2 mM), inhibits the activity of HDAC1 (IC₅₀=400 μM), and induces the degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits the proliferation of small cell lung cancer (SCLC) cells. Valproic acid is used in the study of epilepsy, bipolar disorder, metabolic diseases, HIV infection, and migraine .

HY-10585S

Valproic acid-d4 1 Publications Verification VPA-d₄; 2-Propylpentanoic acid-d₄	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S1

Valproic acid-d6 VPA-d₆; 2-Propylpentanoic acid-d₆	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S2

Valproic acid-d15 VPA-d₁₅; 2-Propylpentanoic acid-d₁₅	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-124087

(±)-2-Propyl-4-pentenoic acid 4-en-VPA; 2-Allylpentanoic acid	Drug Metabolite	Others
(±)-2-Propyl-4-pentenoic acid (4-en-VPA) is a major toxic metabolite of Valproic acid. (±)-2-Propyl-4-pentenoic acid exhibits neuroteratogenicity .

HY-33358

Valproic acid impurity 1	Drug Intermediate	Others
Valproic acid impurity 1 is an impurity of Valproic acid (HY-10585).

HY-10585AR

Valproic acid sodium (Standard) Sodium Valproate (Standard); VPA sodium (Standard); 2-Propylpentanoic acid sodium (Standard)	Organoid Reference Standards HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585S4

Valproic acid-d4-1 VPA-d₄-1; 2-Propylpentanoic acid-d₄-1	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585B

Valproic acid sodium (2:1) Sodium Valproate (2:1); VPA sodium (2:1); 2-Propylpentanoic acid sodium (2:1)	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-B0430B

(±)-Pantothenic acid (±)-Pantothenate; (±)-Vitamin B5	Endogenous Metabolite	Neurological Disease Metabolic Disease
(±)-Pantothenic acid ((±)-Pantothenate), a B-vitamin, is an essential vitamin required for the biosynthesis of coenzyme A (CoA) in mammalian cells. Pantothenic acid has protective activity against valproic acid (VPA)-induced neural tube defects (NTD) in CD-1 mice .

HY-W400496

Valproic acid β-D-glucuronide	HDAC	Cancer
Valproic acid β-D-glucuronide is the major urinary metabolite of Valproic acid (HY-10585) .

HY-118783

2-Hexyl-4-pentynoic acid (±)-2-Hexyl-4-pentynoic acid	HDAC HSP	Neurological Disease Cancer
2-Hexyl-4-pentynoic acid ((±)-2-Hexyl-4-pentynoic acid), a Valproic acid (HY-10585) derivative, exhibits potential roles of HDAC inhibition (IC₅₀ = 13 μM) and HSP70 induction. 2-Hexyl-4-pentynoic acid causes histone hyperacetylation and protect against glutamate-induced excitotoxicity in cultured neurons. 2-Hexyl-4-pentynoic acid can be used for the study of breast carcinoma. 2-Hexyl-4-pentynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

HY-W794759

Valproic acid magnesium Magnesium valproate; VPA magnesium; 2-Propylpentanoic acid magnesium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Cancer
Valproic acid magnesium (Magnesium valproate) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM. Valproic acid magnesium inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid magnesium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid magnesium is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585AS1

Valproic acid-d14 sodium Sodium Valproate-d14; VPA-d14 sodium; 2-Propylpentanoic acid-d14 sodium	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585AS

Valproic acid-d7 sodium Sodium Valproate-d7; VPA-d7 sodium; 2-Propylpentanoic acid-d7 sodium	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S3

Valproic acid-d4 sodium Sodium Valproate-d4; VPA-d4 sodium; 2-Propylpentanoic acid-d4 sodium	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585AG

Valproic acid sodium Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-33358R

Valproic acid impurity 1 (Standard)	Reference Standards
2-Ethyl-2-methylpentanoic acid (Standard) is the analytical standard of 2-Ethyl-2-methylpentanoic acid. This product is intended for research and analytical applications.

HY-178941

DHODH-IN-32	Dihydroorotate Dehydrogenase Apoptosis Caspase Reactive Oxygen Species (ROS)	Cancer
DHODH-IN-32 (Compound A1) is a DHODH inhibitor. DHODH-IN-32 shows significant cytotoxicity against NCI-60 cell lines, especially being sensitive to breast cancer, prostate cancer and leukemia cell lines. DHODH-IN-32 can induce cell apoptosis by activating the Caspase pathway. DHODH-IN-32 causes G0/G1 phase cell cycle arrest and inhibits cellular metabolism by ROS. DHODH-IN-32 exhibits significant anti-tumor properties in mouse breast cancer models. DHODH-IN-32 can be used for the study of breast cancer .

HY-W769286

Valproic acid β-D-glucuronide-d15	Isotope-Labeled Compounds HDAC	Cancer
Valproic acid β-D-glucuronide-d₁₅ is the deuterium labeled Valproic acid β-D-glucuronide (HY-W400496). Valproic acid β-D-glucuronide is the major urinary metabolite of Valproic acid (HY-10585) .

HY-W700378

Valproic acid β-D-glucuronide-d6-1	Isotope-Labeled Compounds HDAC	Cancer
Valproic acid β-D-glucuronide-d₆-1 is the deuterium labeled Valproic acid β-D-glucuronide (HY-W400496). Valproic acid β-D-glucuronide is the major urinary metabolite of Valproic acid (HY-10585) .

HY-133160

Valproic acid hydroxamate VPA-HA	Drug Derivative	Neurological Disease
Valproic acid hydroxamate (VPA-HA) has shown anticonvulsant activity in a mouse neural tube defect model, without any teratogenic effects .

HY-CE01078

3-Oxo-valproicacid-CoA 3-Oxo-Valproic acid coenzyme A	Biochemical Assay Reagents	Metabolic Disease
3-Oxo-valproicacid-CoA (3-Oxo-valproic acid coenzyme A) is a derivative of coenzyme A .

HY-124087R

(±)-2-Propyl-4-pentenoic acid (Standard) 4-en-VPA (Standard); 2-Allylpentanoic acid (Standard)	Reference Standards Drug Metabolite	Others
(±)-2-Propyl-4-pentenoic acid (Standard) is the analytical standard of (±)-2-Propyl-4-pentenoic acid. This product is intended for research and analytical applications. (±)-2-Propyl-4-pentenoic acid (4-en-VPA) is a major toxic metabolite of Valproic acid. (±)-2-Propyl-4-pentenoic acid exhibits neuroteratogenicity[1][2].

HY-114992

2-Propyl-2-pentenoic acid	Drug Metabolite	Neurological Disease
2-Propyl-2-pentenoic acid is a metabolite of Valproic acid (HY-10585). 2-Propyl-2-pentenoic acid has a facilitating action on the acquisition of conditioned behavior with negative reinforcement in mice .

HY-B2117R

Valpromide (Standard)	Reference Standards Epoxide Hydrolase EBV	Infection Neurological Disease
Valpromide (Standard) is the analytical standard of Valpromide (HY-B2117). This product is intended for research and analytical applications. Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle .

HY-W587840S

Valproic acid methyl ester-d3	Isotope-Labeled Compounds	Others
Valproic acid methyl ester-d₃ is the deuterium labeled Valproic acid methyl ester.

HY-W700065

*2,4-Diene-valproic* acid** 2,4-VPA	Drug Metabolite	Others
2,4-Diene-valproic acid (2,4-VPA), a methyl-branched fatty acid, is a metabolite of Valproic acid (HY-10585) .

HY-W400421

3-Hydroxyvalproic acid 3-Hydroxy VPA	Endogenous Metabolite	Metabolic Disease
3-Hydroxyvalproic acid (3-Hydroxy VPA) is a metabolite of valproic acid. 3-Hydroxyvalproic acid is a weak inhibitor of enzymes related to the mitochondrial β-oxidation pathway. 3-Hydroxyvalproic acid is promising for research of diseases related to abnormal valproic acid metabolism .

HY-CE00551

2-Ene-valproicacid-CoA 2-Ene-Valproic acid-coenzyme A	Biochemical Assay Reagents	Metabolic Disease
2-Ene-valproicacid-CoA (2-Ene-valproic acid-coenzyme A) is a coenzyme A derivative.

Cat. No.	Product Name	Type

HY-10585AG

Valproic acid sodium Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Fluorescent Dye
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Valproic acid sodium

Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium

Fluorescent Dye

Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Cat. No.	Product Name	Type

HY-10585AG

Valproic acid sodium Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Biochemical Assay Reagents
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Valproic acid sodium

Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10585

Valproic acid 60+ Cited Publications VPA; 2-Propylpentanoic acid; Dipropylacetic acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585A

Valproic acid sodium 60+ Cited Publications Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Infection Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585AR

Valproic acid sodium (Standard) Sodium Valproate (Standard); VPA sodium (Standard); 2-Propylpentanoic acid sodium (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Organoid Reference Standards HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585B

Valproic acid sodium (2:1) Sodium Valproate (2:1); VPA sodium (2:1); 2-Propylpentanoic acid sodium (2:1)	Infection Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-B0430B

(±)-Pantothenic acid (±)-Pantothenate; (±)-Vitamin B5	Other disease Disease markers Endogenous metabolite	Endogenous Metabolite
(±)-Pantothenic acid ((±)-Pantothenate), a B-vitamin, is an essential vitamin required for the biosynthesis of coenzyme A (CoA) in mammalian cells. Pantothenic acid has protective activity against valproic acid (VPA)-induced neural tube defects (NTD) in CD-1 mice .

Cat. No.	Product Name	Chemical Structure

HY-10585S

Valproic acid-d4 1 Publications Verification
Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

Valproic acid-d4

1 Publications Verification

Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S1

Valproic acid-d6
Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

Valproic acid-d6

Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S2

Valproic acid-d15

Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S4

Valproic acid-d4-1

Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585AS1

Valproic acid-d14 sodium

Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585AS

Valproic acid-d7 sodium

Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S3

Valproic acid-d4 sodium

Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-W769286

Valproic acid β-D-glucuronide-d15
Valproic acid β-D-glucuronide-d₁₅ is the deuterium labeled Valproic acid β-D-glucuronide (HY-W400496). Valproic acid β-D-glucuronide is the major urinary metabolite of Valproic acid (HY-10585) .

HY-W700378

Valproic acid β-D-glucuronide-d6-1
Valproic acid β-D-glucuronide-d₆-1 is the deuterium labeled Valproic acid β-D-glucuronide (HY-W400496). Valproic acid β-D-glucuronide is the major urinary metabolite of Valproic acid (HY-10585) .

HY-W587840S

Valproic acid methyl ester-d3
Valproic acid methyl ester-d₃ is the deuterium labeled Valproic acid methyl ester.

Cat. No.	Product Name		Classification

HY-118783

2-Hexyl-4-pentynoic acid (±)-2-Hexyl-4-pentynoic acid		Alkynes
2-Hexyl-4-pentynoic acid ((±)-2-Hexyl-4-pentynoic acid), a Valproic acid (HY-10585) derivative, exhibits potential roles of HDAC inhibition (IC₅₀ = 13 μM) and HSP70 induction. 2-Hexyl-4-pentynoic acid causes histone hyperacetylation and protect against glutamate-induced excitotoxicity in cultured neurons. 2-Hexyl-4-pentynoic acid can be used for the study of breast carcinoma. 2-Hexyl-4-pentynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10585AG

Valproic acid sodium Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Valproic

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Natural
Products